SBRT/SABR for Oligometastases: The Promise and The Peril - Best of ASTRO 2019
With increasing frequency, local therapy in the form of SBRT or hypofractionated radiation is being applied to patients with oligometastatic cancers as a means of attempting to improve survival outcomes, durability of systemic therapy treatment responses, etc. However, it is apparent that not all of these indications are driven by evidence-based approaches or data from larger scale clinical trials. With this session, we aim to provide an updated view of the principles relevant to treatment of oligometastatic disease and the data supporting its utilization.
This activity is available from December 23,2019 through 11:59 p.m. Eastern time on December 22, 2022.
This activity was originally recorded at ASTRO’s 2019 Best of ASTRO, November 14-16, 2019 in Washington, DC.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, radiation therapists, and radiation dosimetrists.
- Summarize what evidence exists for the use of local therapy for oligometastatic cancers
- Identify the continued questions that exist with regard to optimization of local therapy for oligometastatic cancers, i.e. optimal dose of radiation, timing of treatment (front line vs consolidation vs oligoprogression), integration with systemic therapy such as immunotherapy (for abscopal benefit), etc.
- Describe active trials or ones under development that will provide a stronger basis for changes in standards of care for local therapy use in oligometastatic disease states.
Laura Dawson, MD, is employed by Princess Margaret Hospital, Toronto, Canada and has financial relationships to disclose.
Puneeth Iyengar, MD, PhD, is employed by University of Texas Southwestern, Dallas and has no financial relationships to disclose.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.